GLPwatch
Papers (10409)
Page 128 of 174, ranked by citation count.
- GLP-1 receptor agonists in obesity treatment: Effects on cardiometabolic variables and cardiovascular disease.
- Exendin-4(1-32)K-Capric Acid, a Glucagon-Like Peptide-1 Receptor Agonist, Suppresses Food Intake via Arcuate Pro-Opiomelanocortin Neurons.
- Pancreatic Polypeptide Cell Proliferation in the Pancreas and Duodenum Coexisting in a Patient With Pancreatic Adenocarcinoma Treated With a GLP-1 Analog.
- Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial.
- Weight Outcomes With Empagliflozin as Compared With Liraglutide in Veterans With Type 2 Diabetes Mellitus.
- [Bydureon: first once weekly GLP-1 receptor agonist (exenatide LAR)].
- Tirzepatide increased force of contraction in the isolated human atrium.
- Oral semaglutide: an OASIS from injectables.
- Weight change from incretin-based weight loss medications across categories of second-generation antipsychotics.
- Feasibility of once weekly exenatide-LAR and enhanced diabetes care in Indigenous Australians with type 2 diabetes (Long-acting-Once-Weekly-Exenatide laR-SUGAR, 'Lower SUGAR' study).
- A retrospective observational study on case reports of adverse drug reactions (ADRs) to tirzepatide.
- Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy and Body Weight in Adults With Overweight or Obesity.
- GLP-1 receptor agonism and GIP receptor antagonism induce substantial alterations in enteroendocrine and islet cell populations in obese high fat fed mice.
- In adults with overweight or obesity, continued weekly semaglutide after a 20-wk run-in improved weight loss.
- Development and validation of stability-indicating assay method and identification of force degradation products of glucagon-like peptide-1 synthetic analog Exenatide using liquid chromatography coupled with Orbitrap mass spectrometer.
- Obesity and Schizophrenia: Results of a Feasibility Study with Semaglutide to Assist Weight Loss.
- Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes.
- Safety and Effectiveness of Tirzepatide Use in Obesity Without Type 2 Diabetes Mellitus.
- Liraglutide pharmacokinetics and exposure-response in pediatric patients with type 2 diabetes.
- Analysis on difference in gastrointestinal hormone levels of patients with the history of diabetes and concurrent nephropathy and study on the role of liraglutide.
- GLP1R agonists: primary cardiovascular prevention and oral administration.
- Obesity Treatment: A Focus on Pharmacotherapy of Weight Management.
- Semaglutide and the pathogenesis of progressive neurodegenerative disease: the central role of mitochondria.
- Effect of Semaglutide on C-peptide levels in patients with type 2 diabetes.
- Mazdutide: First Approval.
- Exendin-4 effects on islet volume and number in the mouse pancreas.
- Semaglutide augments vascular proliferation and cardiac performance in a large animal model of ischemic cardiomyopathy.
- Predictive factors for HbA1c and weight loss associated with semaglutide treatment in type 2 diabetes mellitus: real-world clinical evidence.
- Achieving normoglycaemia with tirzepatide: Post hoc exploratory analysis of the SURPASS J-mono and J-combo studies.
- Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWIND.
- Semaglutide and weight loss - A concern for diabetics and pharmaceuticals.
- Enhancing GLP-1 expression via IVT mRNA and fusion protein technology for diabetes therapy.
- Reactivity of N terminal histidine of peptides towards excipients/impurity of excipients: A case study of liraglutide excipient compatibility study.
- Diabetes Mellitus and Cardiovascular Disease: An Evidence-Based Review of Provincial Formulary Coverage.
- Efficacy and Safety of Once Weekly Dulaglutide in East Asian Patients with Type 2 Diabetes: Subgroup Analysis by Potential Influential Factors.
- Multi-database pharmacovigilance assessment of GLP-1 receptor agonist-related ophthalmic risks using advanced signal detection in FAERS and vigibase.
- Weekly Journal Scan: improved renal outcomes by semaglutide in patients with chronic kidney disease and type 2 diabetes in FLOW trial.
- In type 1 diabetes, adding liraglutide to insulin increased hypoglycemia and hyperglycemia with ketosis.
- New-Onset Atrial Fibrillation Potentially Associated With Tirzepatide: A Case Report.
- Reduction of Hepatic Fat Content by Dulaglutide for the Treatment of Diabetes Mellitus: A Two-Centre Open, Single-Arm Trial.
- Exenatide implant therapy in diabetes.
- Extending the reach of Exendin-4: new pathways in the control of body weight and glucose homeostasis.
- Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare.
- Budget impact of introducing oral semaglutide to the public healthcare benefit package in Saudi Arabia.
- GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis.
- The impact of oral semaglutide on glycemic control and weight reduction: a database analysis of dosing effects in Japanese individuals with type 2 diabetes.
- Physiology of the Weight Loss Plateau after Calorie Restriction, GLP-1 Receptor Agonism, and Bariatric Surgery.
- Utilization patterns of glucagon like Peptide-1 receptor agonists prior to bariatric and metabolic surgery: a multicenter study.
- Liraglutide is an effective drug for the treatment of obesity also in real life.
- Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial.
- From diabetes to dopamine: Evaluating the disease-modifying potential of GLP-1 receptor agonists in Parkinson's disease. A systematic review and meta-analysis of placebo-controlled trials.
- Liraglutide combined with HIIT preserves contractile apparatus and blunts the progression of heart failure in diabetic cardiomyopathy rats.
- Case Report: Amelioration of severe metabolic dysfunction-associated steatohepatitis after switching from conventional GLP-1RAs to tirzepatide.
- Evaluating the Efficacy of ChatGPT vs. Google Gemini in Generating Patient Education Materials for GLP-1 Receptor Agonists (Semaglutide, Liraglutide, Tirzepatide): A Cross-Sectional Study.
- PIONEER REAL Saudi Arabia: A multicentre, prospective, real-world study of once-daily oral semaglutide use in adults with type 2 diabetes in Saudi Arabia.
- AI-Driven De Novo Design of Ultra Long-Acting GLP-1 Receptor Agonists.
- Characterizing the D-Amino Acid Position in Peptide Epimers by Using Higher-Energy Collisional Dissociation Tandem Mass Spectrometry: A Case Study of Liraglutide.
- [Liraglutide: new results in the treatment of type 2 diabetes mellitus].
- Safety Choice Drivers of the Coming Treatment Options for Non-Cirrhotic Metabolic Steatohepatitis.
- Design of experiments approach for the development of a validated method to determine the exenatide content in poly(lactide-co-glycolide) microspheres.